Which neurotransmitter is primarily affected in Parkinson's disease?

Study for the Alterations of Neurological Functions Test. Utilize flashcards and multiple-choice questions. Each question comes with hints and explanations for thorough understanding. Get ready to excel!

Multiple Choice

Which neurotransmitter is primarily affected in Parkinson's disease?

Explanation:
The primary neurotransmitter affected in Parkinson's disease is dopamine. In Parkinson's disease, there is a progressive degeneration of dopaminergic neurons, particularly in the substantia nigra region of the brain, which is crucial for coordinating movement. Dopamine plays a key role in the regulation of motor control, and its deficiency leads to the hallmark symptoms of Parkinson's, including tremors, rigidity, and bradykinesia (slowness of movement). Understanding the role of dopamine is essential as it directly impacts the motor pathways involved in movement and coordination. The therapeutic approaches for managing Parkinson's disease often focus on restoring dopamine levels or mimicking its action to alleviate symptoms. This highlights the significance of dopamine in this condition and why it is the neurotransmitter primarily affected in Parkinson's disease.

The primary neurotransmitter affected in Parkinson's disease is dopamine. In Parkinson's disease, there is a progressive degeneration of dopaminergic neurons, particularly in the substantia nigra region of the brain, which is crucial for coordinating movement. Dopamine plays a key role in the regulation of motor control, and its deficiency leads to the hallmark symptoms of Parkinson's, including tremors, rigidity, and bradykinesia (slowness of movement).

Understanding the role of dopamine is essential as it directly impacts the motor pathways involved in movement and coordination. The therapeutic approaches for managing Parkinson's disease often focus on restoring dopamine levels or mimicking its action to alleviate symptoms. This highlights the significance of dopamine in this condition and why it is the neurotransmitter primarily affected in Parkinson's disease.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy